Cologne, Germany, October 22, 2026
Boehringer Ingelheim and Microsoft have announced a strategic collaboration to advance artificial intelligence (AI)-powered clinical development, focusing on digital patient twins and their potential to improve clinical trial design. The partnership aims to make clinical research more patient-centric, strengthen evidence generation and potentially bring safe and effective medicines to patients sooner. Through the collaboration, the pharmaceutical company will combine its drug development expertise with Microsoft’s AI and engineering capabilities to investigate computational models that simulate disease progression and predict treatment outcomes. The research will initially focus on lung health, with opportunities to explore additional therapeutic areas in the future. The initiative reflects the growing role of AI in pharmaceutical research and development, where advanced analytics and predictive modelling could help researchers design more efficient studies while maintaining scientific quality, patient safety and regulatory compliance.
Digital Patient Twins Could Transform Clinical Research
A central objective of the partnership is to investigate Digital Patient Twins, computational representations of individual patients created using clinical and other relevant data. These models are designed to estimate how diseases may progress and how treatment outcomes could change under different scenarios. By studying these predictions, researchers may gain additional insights into disease behaviour, patient variability and potential treatment responses before or during clinical development. Boehringer Ingelheim and Microsoft intend to investigate disease-progression modelling, predictive outcome modelling and advanced clinical trial simulations. These approaches could help research teams assess different trial designs and better understand the potential outcomes of experimental treatments. The partners will use modelling, prototyping and evidence generation to evaluate the scientific and technical feasibility of the technology across selected disease areas. Digital patient twins are an investigational research approach, not replacements for real patients or established clinical evidence. Their usefulness will depend on the quality of the underlying data, the reliability of the models and their validation for specific research applications. The collaboration therefore represents an exploratory effort to determine where AI-based simulations can provide meaningful support to clinical development.
AI Models May Support More Efficient Trial Designs
Another important area of research is the potential use of synthetic and hybrid control arms in clinical trials. Conventional randomized studies commonly compare an investigational medicine with a control group receiving standard treatment or placebo, depending on the study design. A synthetic control arm uses suitable existing data to construct a comparison group, while a hybrid control arm combines existing data with information from participants in a conventional control group. The partners plan to investigate whether digital patient twins and advanced modelling could support these approaches in appropriate clinical research settings. If validated and accepted for specific applications, such methods could potentially reduce the number of participants needed in control groups, improve trial planning and accelerate the generation of clinical evidence. This could be particularly valuable in studies involving complex diseases or patient populations that are difficult to recruit. However, AI-generated control data cannot automatically replace conventional trial controls. Researchers must establish that the data are sufficiently comparable, that potential biases are addressed and that the methods meet applicable regulatory expectations. The companies have emphasized that scientific quality, patient safety and regulatory requirements will remain essential throughout the collaboration.
Advertisement
Lung Health Leads Broader AI Drug Development Strategy
The collaboration will begin with lung health and may subsequently expand into other disease and therapeutic areas as the research progresses. For Boehringer Ingelheim, the initiative supports its broader strategy to integrate AI responsibly across human pharmaceuticals, animal health and business operations. The company is also working to expand employee AI capabilities through technology adoption, skills development and governance frameworks. Microsoft contributes expertise in AI systems, engineering and secure technology infrastructure, supporting the development and evaluation of computational approaches for pharmaceutical research. Beyond clinical development, the organizations are exploring potential co-development opportunities in Animal Health, business processes, security and data centre modernization. These efforts aim to establish a secure and scalable foundation for future AI-enabled innovation. The partnership does not announce a newly approved medicine or guarantee that clinical trials will become shorter; instead, it establishes a research framework to test whether AI can improve selected stages of drug development. Future progress will depend on scientific validation, the availability of appropriate data and the demonstrated value of the models in real clinical research settings. If successful, the initiative could contribute to more informed clinical trial design and more efficient pharmaceutical development while keeping patient welfare at the centre of innovation.
Source: Boehringer Ingelheim press release
